GeoVax's CM04S1 Vaccine Shows Promise for Immunocompromised Patients in Phase 2 Trials

GeoVax Labs, Inc. will present recent clinical progress for its CM04S1 COVID-19 vaccine candidate at the Emerging Growth Conference on September 25, 2025. The presentation will highlight interim results from Phase 2 trials showing that CM04S1 achieved primary immune response endpoints in chronic lymphocytic leukemia patients where comparator mRNA vaccines failed, with further enrollment proceeding exclusively in the CM04S1 arm based on Data Safety Monitoring Board recommendation.

Additional data presented at European Society of Clinical Microbiology and Infectious Disease meetings demonstrated robust, durable T-cell and cross-variant antibody responses in immunocompromised blood cancer and post-transplant patients, with no serious adverse events reported. These findings reinforce CM04S1's differentiation versus standard-of-care vaccines and underscore its potential as a multi-antigen solution for patients inadequately protected by first-generation COVID-19 vaccines.

The clinical progress is significant because immunocompromised populations, including those with hematologic cancers and transplant recipients, have shown suboptimal responses to currently authorized COVID-19 vaccines. GeoVax's MVA platform appears capable of delivering broad, durable immune protection where it is needed most, potentially reducing severe COVID-19 outcomes in vulnerable patient groups who remain at elevated risk despite vaccination.

GeoVax Chairman and CEO David Dodd will present the data during the live online event, which allows for real-time Q&A participation. The company's lead clinical program involves three Phase 2 trials evaluating CM04S1 as both a primary vaccine for immunocompromised patients and a booster for various populations. A replay will be available following the event on www.EmergingGrowth.com and their YouTube channel.